Research programme: CCR2 antagonists - Janssen Research and Development/Johnson & Johnson

Drug Profile

Research programme: CCR2 antagonists - Janssen Research and Development/Johnson & Johnson

Alternative Names: CCR2 antagonists - Johnson & Johnson/Janssen Research and Development; Chemokine receptor-2 antagonists - Johnson & Johnson; JNJ-27553292

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen Research & Development; Johnson & Johnson
  • Developer Johnson & Johnson
  • Class Azetidines; Cyclohexanes
  • Mechanism of Action CCR2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Allergic rhinitis; Asthma; Autoimmune disorders; Inflammation

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Allergic-rhinitis in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Asthma in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top